Bifidobacterium lactis BB-12
Bifidobacterium animalis subsp. lactis BB-12
The most-studied Bifidobacterium — gentle gut regularity and infant comfort
Evidence tier
Moderate
Research weight
Citations
10 verified / 10
Classification
Probiotics
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Bifidobacterium lactis BB-12?
Bifidobacterium lactis BB-12 (Bifidobacterium animalis subsp. lactis BB-12) is a probiotic strain used for increases defecation frequency in adults with low frequency and mild abdominal discomfort (regularity). NutriDex grades the human evidence as Moderate. Bifidobacterium animalis subsp. lactis BB-12 is the world's most-studied Bifidobacterium, with randomized, placebo-controlled trials supporting modest, strain-specific benefits for bowel regularity and infant comfort. The largest probiotic regularity trial ever published (Eskesen 2015, n=1248) showed BB-12 significantly raised defecation frequency in adults with low frequency and abdominal discomfort, and a colic RCT (Nocerino 2020) found 80% of breastfed colicky infants on BB-12 achieved a >=50% reduction in crying versus 32.5% on placebo. Mechanistic and infant-infection data are supportive but more preliminary, and evidence for preventing antibiotic-associated diarrhea is still emerging rather than definitive for this specific strain.
Purported Benefits
✓Increases defecation frequency in adults with low frequency and mild abdominal discomfort (regularity)
✓Reduces daily crying time in breastfed infants with colic and improves stool frequency/consistency
✓Helps preserve gut microbiome function (fecal short-chain fatty acids) during a course of antibiotics
✓May reduce respiratory tract infections in early infancy
✓Modulates NK and T-cell activity / mucosal immune function in healthy adults
✓Generally improves bowel transit and stool consistency in mild constipation
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Defecation frequency / regularity (adults)Large RCT (Eskesen, n=1248) raised defecation frequency; single trial but well-powered and strain-specific. | Moderate | ↑ benefit · small | 1 |
| Infant colic crying timeOne RCT (Nocerino, n=80 breastfed): 80% vs 32.5% achieved >=50% crying reduction; needs replication. | Preliminary | ↑ benefit · large | 1 |
| Respiratory tract infections (infants/adults)Two RCTs (Taipale infants, Meng adults) reduced RTI occurrence; small and population-specific. | Preliminary | ↑ benefit · small | 2 |
| Microbiome preservation during antibioticsOne RCT (Merenstein) preserved fecal SCFA; surrogate endpoint, not clinical AAD. | Preliminary | ↑ benefit · small | 1 |
| Blood lipidsCrossover RCT (Matsumoto, n=30) found no change in cholesterol or triglycerides. | Preliminary | — no effect · negligible | 1 |
Dosing & Compounds
Typical Dose
Trials used roughly 1 x 10^9 to 1 x 10^10 CFU/day, taken once daily. Adult regularity trials showed no added benefit above 1 billion CFU/day (a ceiling effect), and the infant colic trial used 1 billion CFU/day for 28 days. Effects on bowel function typically appear over 2-4 weeks of continuous use; can be taken with or without food.
Active Compounds
Safety & Cautions
Very well tolerated in trials, including healthy adults, children, and infants; meta-analysis of adverse events found no significant safety signal versus placebo. Mild gas, bloating, or transient stool changes can occur. As with all live probiotics, use caution in critically ill, severely immunocompromised, or central-line patients, in whom rare probiotic bacteremia has been reported across the field; discuss with a clinician before use in these groups. Educational only — always check with your doctor or pharmacist before combining Bifidobacterium lactis BB-12 with any medicine.
Key Studies ★ 10 studies
Meta-analysis
Garzon Mora 2024 (Cureus)
✓ Full text
Systematic review and meta-analysis of 10 studies (1,243 patients) found probiotics significantly favored over placebo for constipation treatment (p<0.05), though with high heterogeneity (I2=95%).
Meta-analysis
Bowel-movement meta-analysis 2024 (PMC)
✓ Full text
Systematic review and meta-analysis of probiotic-containing products in adult functional constipation found significant improvement in bowel movement frequency, with greater effect for combined Lactobacillus + Bifidobacterium than single-genus products.
RCT
IBS RCT 2025
✓ PubMed
Double-blind RCT of L. acidophilus LA-5 + B. animalis lactis BB-12 in non-constipated IBS found higher IBS Global Improvement Scale response with probiotics vs placebo at day 28 (19.3% vs 8.9%; p=0.048).
RCT
Nocerino 2020
✓ Full text
In 80 breastfed colicky infants, 80% on BB-12 (1 billion CFU/day, 28 days) achieved >=50% reduction in daily crying vs 32.5% on placebo, with improved stool frequency and consistency.
RCT
Merenstein 2021
✓ Full text
During amoxicillin/clavulanate, BB-12 yogurt protected fecal microbiome function: acetate returned to baseline (-1.6%) by day 30 in the BB-12 group while remaining suppressed in controls.
RCT
Eskesen 2015
✓ Full text
In 1248 adults with low defecation frequency, BB-12 significantly increased average defecation frequency vs placebo (treatment effect P=0.0065), with no added benefit above 1 billion CFU/day.
RCT
Taipale 2016
✓ Source
In healthy newborns, early BB-12 supplementation reduced the occurrence of respiratory infections vs control (65% vs 94%; RR 0.69, 95% CI 0.53-0.89; P=0.014).
RCT
Meng 2016
✓ Source
BB-12 consumption in healthy adults reduced the incidence/duration of upper respiratory tract infection symptoms and enhanced NK- and T-cell function vs placebo.
RCT
Matsumoto 2017
✓ Full text
In a randomized crossover trial of 30 healthy adults, BB-12 did not significantly alter total, LDL, or HDL cholesterol or triglycerides vs control, indicating no meaningful lipid effect.
Review
Frontiers in Microbiology 2025 (Stenman et al.)
✓ PubMed
Landmark narrative review consolidating decades of human trials confirms B. animalis subsp. lactis BB-12 is effective for low defecation frequency and infant colic, and one of the most clinically documented probiotic strains.